SCHEMBL23218877

SCHEMBL23218877

CC(C)(C)c1oc2ccc(Br)cc2c1CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.41
PIM1 P11309 1/20 0.41
MAPT P10636 4/20 0.40
CA12 O43570 3/20 0.38
CA9 Q16790 3/20 0.38
LMNA P02545 2/20 0.38
CASP6 P55212 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218435 0.79 KCNH2 (0.47) KCNH2PIM1MAPTCA12CA9
SCHEMBL29853136 0.79 KCNH2 (0.47) KCNH2PIM1MAPTCA12CA9
SCHEMBL23218349 0.77 PIM1 (0.49) KCNH2PIM1MAPTCA12CA9
SCHEMBL23218211 0.76 KCNH2 (0.42) KCNH2PIM1MAPTCA12CA9
SCHEMBL29853267 0.76 KCNH2 (0.42) KCNH2PIM1MAPTCA12CA9
SCHEMBL23218086 0.76 PIM1 (0.45) KCNH2PIM1MAPTCA12CA9
SCHEMBL29852587 0.76 PIM1 (0.45) KCNH2PIM1MAPTCA12CA9
SCHEMBL29852875 0.74 PIM1 (0.43) KCNH2PIM1MAPTCA12CA9
SCHEMBL23218189 0.74 PIM1 (0.43) KCNH2PIM1MAPTCA12CA9
SCHEMBL10851844 0.73 ESR1 (0.43) KCNH2PIM1MAPTCA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KCNH2 839/4885PIM1 4538/4885MAPT 4793/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KCNH2 4027/4885PIM1 4497/4885MAPT 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.